Stock listing

Pliant Therapeutics, Inc.

Selected listing: A2P4YV · LS · EUR · DE

Pliant Therapeutics, Inc. (Lang & Schwarz: A2P4YV), Health Technology. Latest release Sep 30, 2026: Pliant Therapeutics Appoints David Raben, M.D., as Chief…

A2P4YV:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A2P4YV
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: Lang & Schwarz
Currency: EUR

Latest news from Pliant Therapeutics, Inc.

Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer

September 30, 2026

Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer

September 29, 2026

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

August 18, 2026

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 11, 2026

Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors

July 13, 2026

All Pliant Therapeutics, Inc. news →

Research Pliant Therapeutics, Inc.

Pliant Therapeutics, Inc. company profile

View the public company page for Pliant Therapeutics, Inc. on 6ix.

Pliant Therapeutics, Inc. news

Read company news and market updates connected to Pliant Therapeutics, Inc..

Pliant Therapeutics, Inc. investor events

Find investor webinars, events, and replay context for Pliant Therapeutics, Inc..